Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.
Choose from the criteria below to find an activity that fits you best.
Note: If you attended the live CE activity AND received CE credit (i.e.
a pharmacist CE statement of credit with ACPE UAN 0221-9999-19-505-L01-P), you are
NOT allowed to also receive credit for this home-study on-demand web activity.
|Co-produced by ProCE, the National Association of Specialty Pharmacy (NASP), and AllianceRx Walgreens Prime.|
Pulmonary arterial hypertension (PAH) is most often first encountered in pulmonary, cardiac, and critical care settings. The mean time to clinical PAH diagnosis averages 3 years, resulting in a tremendous treatment gap of PAH patients during the easier-to-manage initial phases of the disease. This activity will focus on individualized treatment strategies for PAH therapy. The format will utilize a patient case presentation to highlight therapeutic approaches to manage PAH with a focus on continual reevaluation and therapy adjustment, and on the role of the interprofessional patient care team. This activity will cover insights into PAH pathophysiology, therapies and the most recent data surrounding their uses, and navigating clinical guidelines. Participants will better understand opportunities for patient education and an interprofessional approach to best practices for transitions of care.
The target audience for this activity includes pharmacists and nurses including those practicing in pulmonary diseases, critical care, specialty pharmacies, and managed care entities. At the completion of this activity, the participant will be better able to:
Matt Casciano, PharmD, BCPS
Clinical Pharmacy Specialist - Pulmonary
UCHealth University of Colorado Hospital
Pol-Andre Senecal, MSN, NP, CNS, ACNP, CCNS
Instructor of Medicine
Pulmonary Vascular Disease & Critical Care Medicine
Lead Advanced Practice Provider
Division of Pulmonary Sciences and Critical Care Medicine
University of Colorado School of Medicine
Release Date: 12-11-2019
Expiration Date: 1-17-2021
This activity is jointly provided by ProCE, Inc. and the Illinois Council of Health-System Pharmacists (ICHP), in partnership with the National Association of Specialty Pharmacy (NASP) and AllianceRX Walgreens Prime. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-505-H01-P has been assigned to this home study knowledge-based activity (initial release date 12-11-19). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. Statements of completion will be issued online at www.ProCE.com and proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
This CE activity is jointly provided by ProCE, Inc., the Illinois Council
of Health-System Pharmacists and Wild Iris Medical Education, Inc. This activity provides
1.5 contact hours of nurse CE credit.
Wild Iris Medical Education, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and
scientific rigor in all of its continuing education activities. Faculty must disclose
to participants any significant financial interest or affiliation with companies that
manufacture or market products discussed during their presentation. Dr. Casciano has
no relevant commercial or financial relationships to disclose. Mr. Senecal has no
relevant commercial or financial relationships to disclose. A portion of grant funds
received by ProCE from Actelion Pharmaceuticals US, Inc. will be used to compensate
the faculty for this presentation.
Please note: The opinions expressed in this activity should not be construed as those of the CE providers, NASP, AllianceRx Walgreens Prime or Actelion Pharmaceuticals US, Inc. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the discussion of drugs for unlabeled indications. Use of drugs outside of labeling should be considered experimental, and participants are advised to consult prescribing information and professional literature.
This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.